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CC BY-NC-ND license (http://creativeRotaviruses (RVs) are a major cause of acute gastroenteritis in infants and young children
worldwide. These viruses infect the villous epithelium of the small intestine. Part of their
replication occurs in cytoplasmic inclusion bodies termed viroplasms. Viroplasms and the lipid
droplets (LDs) of cellular organelles are known to interact both physically and functionally.
Compounds interfering with the homoeostasis of LDs significantly decrease the production of
infectious RV progeny. There is considerable scope for more detailed exploration of such com-
pounds as potential antiviral agents for a disease for which at present no specific therapy ex-
ists.
Copyright ª 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Globally, rotaviruses (RVs) are a major cause of acute
gastroenteritis (AGE) in infants and young children and in
the young of a large variety of mammalian and avian spe-
cies.1 RV-associated diseases led to nearly half a million
deaths of infants and young children in 2008, mainly in
countries of sub-Saharan Africa and Southeast Asia.2 Two
live-attenuated RV vaccines, licensed since 2006, are now
incorporated into expanded programs on immunization forhave no conflicts of interest
of Medicine, Addenbrooke’s
ls Road, Cambridge CB2 0QQ,
m.ac.uk (A. Lever).
6.02.004
an Medical Association. Published
commons.org/licenses/by-nc-nd/children in many countries including areas of the devel-
oping world.3 The universal use of RV vaccines has resulted
in reduced hospital admissions and outpatient doctors’
consultations for RV-associated AGE in numerous set-
tings.4,5 In some countries, RV vaccination also has reduced
mortality from RV-associated diseases6,7; in 2012, the es-
timate of RV-associated deaths worldwide in children aged
under 5 years was reduced to approximately 200,000.8
Despite this promising trend, the clinician facing a patient
with severe RV-induced diarrhea has no specific therapy
other than supportive measures, and there is no prophylaxis
other than vaccination to offer to susceptible contacts.
Herein we describe some novel findings about RV replica-
tion, which demonstrate a growing theme in microbiology:
the role of lipid droplets (LDs) in the lifecycle of various
pathogens. The research outcomes raise the possibility of
exploiting this characteristic feature and investigating
previously unexplored approaches to have better controlby Elsevier Taiwan LLC. This is an open access article under the
4.0/).
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humans and other animals.
RV classification
RVs form a genus of the Reoviridae family and are further
subdivided into different groups/species (AeH) and types
within groups.9,10 The RV genome consists of 11 segments of
double-stranded RNA (dsRNA) encoding six structural and
six nonstructural (NS) proteins. RV types are distinguished
by their surface proteins, VP7 and VP4, as G types and P
types, respectively. There are at least 27 different G and 37
different P types within Group A RVs, demonstrating the
very high degree of diversity of these viruses.11 More
recently, genotypes of all RV RNA segments have been
differentiated.9,11
RV replication
After adsorption onto and entry into susceptible cells in the
gut and partial uncoating, RVs produce single-stranded RNA
transcripts, which extrude into the cytoplasm and translate
into viral proteins. Further viral propagation takes place in
cytoplasmic inclusion bodies termed viroplasms, where
subviral particles are assembled and viral RNA replication
occurs. The RV NS proteins NSP2 and NSP5 are essential for
the formation of viroplasms. No viroplasm formation, viral
RNA replication, or production of infectious progeny are
seen when the expression or functions of either NSP2 or
NSP5 are blocked.12e14 Subviral double-layered particles
(DLPs) are released from viroplasms and mature in the
cytoplasm to become triple-layered particles (TLPs) infec-
tious virions, which are released by cell lysis or are
extruded without immediate cytopathicity.1
Interaction of viroplasms with LDs
During studies on RV replication, our laboratory discovered
the interaction of viroplasms with cellular LDs.15 LDs are
the principal intracellular storage sites of triacylglycerols,
sterol esters, and cholesterol.16e18 LDs are surrounded by a
phospholipid monolayer into which perilipin, adipophilin,
and various other cellular proteins are inserted.17,19e21
It was shown that RV-induced viroplasms interact with
LDs physically and functionally.15 Using confocal micro-
scopy and fluorescence resonance energy transfer, a phys-
ical association between viroplasms and LD-associated
proteins and lipids was confirmed (Figure 1). Furthermore,
it was observed that viroplasms recruit LDs from 4 hours to
6 hours postinfection (p.i.) during the later stages of RV
replication.15 However, more detailed mechanisms of the
viroplasmeLD interaction remain to be elucidated.
After ultracentrifugation of a detergent-free extract of
RV-infected cells with iodixanol gradients it was observed
that LDmarkers such as perilipin A cosediment in low-density
fractions (1.11e1.15 g/mL) with viroplasm markers (NSP2 or
NSP5) and with a peak of RV dsRNA replicated in viroplasms.
By contrast, spiking of uninfected cell extracts with purified
RV DLPs did not lead to their cosedimentation with LD
markers; instead, the subviral particles remained assediments at the bottom of the gradient tube.15 These ob-
servations strengthened the evidence for the physical asso-
ciation between viroplasms and LDs. Having shown that LDs
are physically involved in the RV replication cycle, the lip-
idome of RV-infected cells was compared with that of unin-
fected cells.22 Iodixanol-gradient fractions were analyzed
for 14 different classes of lipids by mass spectroscopy.22 The
concentrations of virtually all classes of lipids were elevated
in RV-infected cells compared with uninfected cells. The
low-density fractions of iodixanol gradients mentioned
earlier contained peak amounts of lipids, which are charac-
teristically enriched in LDs, including ceramide, sphingo-
myelin, triglycerides, phosphatidylinositol, and
phosphatidic acid, the direct precursor of triacylglycerol.22
This analysis consolidated the observation that viroplasms
interact with LDs during RV replication and suggested that
beyond a physical association this also had metabolic con-
sequences, which remain to be explored further.
An increase in the lipid content of cells after RV infec-
tion was also reported.23 Kim and Chang23 showed that
activation of the binding of bile acids to their natural far-
nesoid X receptor (FXR) or FXR stimulation correlated with
a reduction of intracellular lipid content and also with a
reduction in the replication of RVs in vitro in a dose-
dependent manner.23 More recently, it was shown that in-
hibitors of lipolysis and inhibitors of fatty acids (FAs)
transport to the mitochondria decreased RV replication by
94% to 97%,24 although the underlying mechanisms of action
remain to be fully understood.Decrease of RV replication by compounds
interfering with LD homoeostasis
Given the apparent physical and functional interactions be-
tweenRVreplicationandLDs, itwasparticularly interesting to
explore whether compounds that affect cellular lipid meta-
bolismandLDhomoeostasis interferewithRVreplication. The
combination of a beta-adrenergic agonist (isoproterenol
isoprenaline) and a phosphodiesterase inhibitor [iso-
butylmethylxanthine (IBMX)] was previously shown to elevate
the intracellular level of cyclic adenosine monophosphate,
thus leading to the phosphorylation of perilipin A and
hormone-dependent lipase, and finally to lipolysisof LDs.25,26
Cells treated concurrently with these two compounds at
nontoxic concentrations produce significantly fewer and
smaller viroplasms upon infection (Figure 2), less viral dsRNA
due to decreased viral RNA replication, and lower titers of
infectious RV progeny (Table 1). Strikingly, the RV-induced
cytopathicity was reduced in the isoprenaline/IBMX-treated
cells, which indicates that inhibition of RV replication also
protected the cells against virus-induced damage.15
Interference with the intracellular biosynthetic path-
ways of FAs also decreased RV replication. Triacsin C, an
inhibitor of the long-chain acyl-coenzyme A (CoA) synthe-
tase,27,28 and its chemical analogs are reported to inhibit
RV replication.15,29 An inhibitor of FA synthase (C75)30
suppressed RV replication consistently, although only
marginally,31 probably due to the low chemotherapeutic
index of this drug. However, treatment with 5-(tetradecy-
loxy)-2-furoic acid (TOFA), an inhibitor of acetyl-CoA
carboxylase 1 (ACC1),32,33 a rate-limiting enzyme in early
Figure 1 Rotavirus protein NSP5 in viroplasms colocalizes with perilipin A (upper row) and lipids (lower row) in lipid droplets.
Scale bar: 10 mm. Note. Modified from “Rotaviruses associate with cellular lipid droplet components to replicate in viroplasms, and
compounds disrupting or blocking lipid droplets inhibit viroplasm formation and viral replication,” by W. Cheung, M. Gill, A.
Esposito, C.F. Kaminski, N. Courousse, S. Chwetzoff et al., 2010, J. Virol., 84, p. 6782e98. Copyright 2010, American Society for
Microbiology. Adapted with permission.
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tion and the infectivity titer of RV progeny, with an in vitro
chemotherapeutic index of between 5 and 12.31 This effect
was still detectable when TOFA was added to RV-infected
cells as late as at 4 hours p.i. Specific small interfering
RNA knockdown of ACC1 produced an effect similar to that
of chemical ACC1 inhibition.31 Table 1 presents a compar-
ison of inhibitory effects of different compounds affecting
LD homoeostasis on rotavirus replication.
It is thus necessary to identify in more detail which of
the cellular genes involved in LD homoeostasis34e36 will be
important for the interaction of LDs with viroplasms, and
thus could affect RV replication.Broader effects of TOFA on RV replication
The CsCl-gradient ultracentrifugation carried out on un-
treated or TOFA-treated RV-infected cells permits the sep-
aration of DLPs noninfectious virions (density 1.38 g/mL) and
TLPs infectious virions (density 1.36 g/mL).37 TOFA treat-
ment caused an approximately twofold reduction in the
production of RV DLPs, but a 20-fold reduction in detectable
TLPs.38 This suggests that the blockage of FA synthesis may
affect RV replication not only at the steps occurring within
viroplasms up to DLP formation, but also at the later steps of
viral maturation in the endoplasmic reticulum.Further research on inhibition of RV
replication by LD-disturbing drugs
So far, the involvement of LDs in RV replication has been
studied primarily in MA104 cells, a cell line derived from
embryonic rhesus monkey kidney and routinely used for RV
propagation in vitro.15 Because RVs replicate in the termi-
nal enterocytes of the epithelium of the small intestine,
the interaction of LDs with viroplasms in RV-infected Caco-2
cells, which are derived from clinical specimens of human
colon carcinoma, and in RV-infected human liver-derived
cells, Huh-7, which have larger LDs than MA104 cells, has
been studied, and effects similar to those described earlier
were observed.39 Infection of HT29 cells with RV in the
presence of nontoxic concentrations of stilbenoids,
cannabinoid receptor antagonists, led to a 10- to 20-fold
decrease of the infectivity of RV progeny; one of the sug-
gested mechanisms of action was interference with lipid
homoeostasis, because stilbenoids are very lipophilic.40
Cellular cholesterol was shown to be critical for bovine RV
replication in MA104 cells at the stages of viral cell entry and
virus assembly.41 However, more work is needed to explore
these interesting observations in-depth. Human intestinal
enteroid cultures showed interaction of viroplasms with
LDs42 (Figure 2H, Ref. 42, and this will permit further study
under more natural pathophysiological conditions.
Treatment of mice with compounds decreasing the
intracellular triglyceride content led to a reduction of RV
shedding on Days 1e3 p.i. when compared with RV-infected,
Figure 2 Treatment of rotavirus-infected cells with a combination of isoproterenol and isobutylmethylxanthine (IBMX) disperses
viroplasms and decreases their number and size: (A) control cells; (B) treated rotavirus-infected cells (a comparison of treated cells
in Panel B with the untreated control in Panel A is presented). Scale bar: 10 mm. Note. From “Rotaviruses associate with cellular
lipid droplet components to replicate in viroplasms, and compounds disrupting or blocking lipid droplets inhibit viroplasm formation
and viral replication,” by W. Cheung, M. Gill, A. Esposito, C.F. Kaminski, N. Courousse, S. Chwetzoff et al., 2010, J. Virol., 84, p.
6782e98. Copyright 2010, American Society for Microbiology. Reprinted with permission.
392 A. Lever, U. Desselbergeruntreated mice.23 Animal models of RV infection and dis-
ease1 should be explored to find out whether compounds
such as isoproterenol þ IBMX and TOFA, which decrease RV
production in vitro, will also reduce RV shedding and/or
diarrhea. Such studies will be a prerequisite for considering
the feasibility and promise of clinical trials in humans.Table 1 Comparison of inhibitory effects of different compound
Treatment of cells Viral double-stra
Relative valuesa
Isoproterenol þ IBMXc  1.00
þ 0.25
Triacsin Cc  1.00
þ 0.26
TOFAd  1.00
þ 0.17
* Statistical difference.
IBMXZ isobutylmethylxanthine; TOFAZ 5-(tetradecyloxy)-2-furoic ac
a Calculated from densitometric values of RNA gels (Cheung, 2010)
b Tissue culture infectious dose 50 percent/mL; standard error valu
c From “Rotaviruses associate with cellular lipid droplet component
lipid droplets inhibit viroplasm formation and viral replication,” by
Chwetzoff et al., 2010, J. Virol., 84, p. 6782e98. Copyright 2010, Am
d From “Inhibition of rotavirus replication by downregulation of fa
Lever, and U. Desselberger, 2013, J. Gen. Virol., 94, p. 1310e7. CopPotential of LD-disturbing drugs as antivirals
RVs have now joined the growing list of microbes that are
dependent on interaction with LDs for their replication,
including viruses such as hepatitis C virus (HCV)43e48;
dengue virus,49 GB virus B, a flavivirus45; bunyavirus50; ands affecting lipid droplet homoeostasis on rotavirus replication.
nded RNA Infectivity of progeny
Difference* log TCID50/mL
b Difference
8.2
Fourfold* 6.5 50-fold*
7.5
3.8-fold* 6.2 20-fold*
8.4
5.9-fold* 6.7 50-fold*
id.
.15
es are not shown.
s to replicate in viroplasms, and compounds disrupting or blocking
W. Cheung, M. Gill, A. Esposito, C.F. Kaminski, N. Courousse, S.
erican Society for Microbiology. Reprinted with permission.
tty acid synthesis,” by E.R. Gaunt, W. Cheung, J.E. Richards, A.
yright 2013, Microbiology Society. Reprinted with permission.
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tuberculosis,52 and Mycobacterium leprae.53 The impor-
tance of lipid metabolism for HCV replication has been
recognized and this knowledge has been used in the context
of successful therapies.54 On a wider scale, FA biosynthesis
has been identified as being an essential step for the
replication of a larger number of viruses such as enterovi-
ruses, West Nile virus, human cytomegalovirus, Kaposi
sarcoma-associated herpes virus, and Epstein-Barr virus,
and lipid metabolic enzymes are considered as potential
broad-spectrum drug targets, with some relevant Food and
Drug Administration-approved drugs already being avail-
able.55 The importance of LDs for hostepathogen in-
teractions is an emerging theme.56,57 There is already proof
of principle in vitro and in vivo that compounds perturbing
LDs have the potential to become candidate therapeutics
for the treatment of RV disease and other microbial dis-
eases. A new and much needed class of antimicrobial drugs
may be in waiting.Acknowledgments
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